Role Professor | Name Rudolf Jaenisch Academic advisors Arnold Levine | |
 | ||
Institutions Max Planck Institute for BiochemistryPrinceton UniversityFox Chase Cancer CenterSalk InstituteHeinrich Pette InstituteUniversity of HamburgWhitehead Institute for Biomedical ResearchMassachusetts Institute of Technology Alma mater University of Munich (M.D., 1967) Known for Epigenetic mechanisms of gene regulationTherapeutic cloningEmbryonic stem cell research Notable awards Boehringer Mannheim Molecular Bioanalytics Prize (1996)Gruber Prize in Genetics (2001)Robert Koch Prize (2002)Max Delbruck Medal (2006)Massry Prize from the Keck School of Medicine (2008)Wolf Prize in Medicine (2011)National Medal of Science (2011) Education Ludwig Maximilian University of Munich Residence Germany, United States of America Awards Wolf Prize in Medicine, Robert Koch Prize, Massry Prize, National Medal of Science for Biological Sciences Similar People Shinya Yamanaka, Kevin Eggan, James Thomson | ||
Organizations founded Fate Therapeutics | ||
2010 Killian Lecture: Rudolph Jaenisch, "Making Stem-cell Therapy a Reality"
Rudolf Jaenisch (born 22 April 1942) is a Professor of Biology at MIT and a founding member of the Whitehead Institute for Biomedical Research. He is a pioneer of transgenic science, in which an animal’s genetic makeup is altered. Jaenisch has focused on creating genetically modified mice to study cancer and neurological diseases.
Contents
- 2010 Killian Lecture Rudolph Jaenisch Making Stem cell Therapy a Reality
- Genetic manipulation in stem cells rudolf jaenisch
- Research
- Career
- Awards and honors
- References
Genetic manipulation in stem cells rudolf jaenisch
Research
Jaenisch’s first breakthrough occurred in 1974 when he and Beatrice Mintz showed that foreign DNA could be integrated into the DNA of early mouse embryos. They injected retrovirus DNA into early mouse embryos and showed that leukemia DNA sequences had integrated into the mouse genome and also to its offspring. These mice were the first transgenic mammals in history.
His current research focuses on the epigenetic regulation of gene expression, which has led to major advances in creating embryonic stem cells and “induced pluripotent stem" (IPS) cells, as well as their therapeutic applications. In 2007, Jaenisch’s laboratory was one of the first three laboratories world-wide to report reprogramming cells taken from a mouse's tail into IPS cells. Jaenisch has since shown therapeutic benefits of IPS cell-based treatment for sickle-cell anemia and Parkinson's disease in mice. Additional research focuses on the epigenetic mechanisms involved in cancer and brain development.
Jaenisch’s therapeutic cloning research deals exclusively with mice, but he is an advocate for using the same techniques with human cells in order to advance embryonic stem cell research. However, in 2001 Jaenisch made a public case against human reproductive cloning, testifying to a U.S. House of Representatives subcommittee and an editorial in Science magazine.
Career
Jaenisch received his doctorate in medicine from the University of Munich in 1967, preferring the laboratory to the clinic. He became a postdoc at the Max Planck Institute in Munich, studying bacteriophages. He left Germany in 1970 for research positions at Princeton University, Fox Chase Institute for Cancer Research and the Salk Institute. He returned to Germany in 1977 to become the head of the Department of Tumor Virology at the Heinrich Pette Institute at the University of Hamburg. He arrived at MIT in 1984. He participated in the 2005 science conference on human cloning at the United Nations and serves on the science advisory boards of the Genetics Policy Institute and Stemgent.